Biomarin Pharmaceutical Inc. [BMRN] stock prices are up 0.07% to $69.85 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BMRN shares have gain 2.48% over the last week, with a monthly amount drifted -17.61%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Bernstein upgraded its rating to Outperform on August 20, 2024, and elevated its price target to $110. On May 17, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $72 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $113 on May 14, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $100 as its price target on November 15, 2023. Bernstein upgraded its rating to Mkt Perform for this stock on October 23, 2023, but kept the price target unchanged to $82. In a note dated September 28, 2023, Raymond James initiated an Mkt Perform rating.
The stock price of Biomarin Pharmaceutical Inc. [BMRN] has been fluctuating between $67.75 and $99.56 over the past year. Currently, Wall Street analysts expect the stock to reach $103.65 within the next 12 months. Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] shares were valued at $69.85 at the most recent close of the market. An investor can expect a potential return of 48.39% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
The Biomarin Pharmaceutical Inc. [NASDAQ:BMRN] reported sales of 2.59B for trailing twelve months, representing a surge of 19.18%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.05 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 69.24 points at the first support level, and at 68.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.17, and for the 2nd resistance point, it is at 70.49.
Ratios To Look Out For
It’s worth pointing out that Biomarin Pharmaceutical Inc. [NASDAQ:BMRN]’s Current Ratio is 3.05. Further, the Quick Ratio stands at 1.95, while the Cash Ratio is 0.91. Considering the valuation of this stock, the price to sales ratio is 5.13, the price to book ratio is 2.52 and price to earnings (TTM) ratio is 52.73.
Transactions by insiders
Recent insider trading involved Burkhart Erin, GVP, Chief Accounting Officer, that happened on Aug 13 ’24 when 714.0 shares were sold. Officer, Burkhart Erin completed a deal on Aug 13 ’24 to buy 714.0 shares. Meanwhile, EVP, Chief Financial Officer Mueller Brian sold 5000.0 shares on May 30 ’24.
